Superworth

Artiva Biotherapeutics revenue ARTV

Sales by quarter and over the last twelve months, from 2023.

Last 12 months, to Dec 31, 2024
n/m
a quarter missing
Latest quarter, Q4 FY24
$0
−100% on a year earlier
Fiscal year 2024
n/a

Artiva Biotherapeutics' twelve-month revenue can't be added up yet: a quarter of its results is missing from our data.

In its latest quarter, Q4 FY24, it was $0, down 100% on the same quarter a year before.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2024n/an/a
FY2023$33.5Mn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q4 FY24$0−100%n/a
Q3 FY24$0−100%n/a
Q4 FY23$2.4Mn/a$33.5M
Q3 FY23$26.7Mn/an/a
Q2 FY23$3.5Mn/an/a
Q1 FY23$990Kn/an/a

Against its peers

Companies in Healthcare nearest Artiva Biotherapeutics' size, closest first, today.

CompanyRevenue, 12 monthsGrowth
ARTVArtiva Biotherapeuticsn/m
PLXProtalix BioTherapeutics$80.6M+30% a year
NATRNatures Sunshine Products$492M+7% a year
ELMDElectromed$73.8M+15% a year
UTMDUtah Medical Products$36.1M−7% a year
PDEXPro DEX$79.6M+13% a year
INFUInfuSystem$143.3M+2% a year
CYHCommunity Health Systems$11.7B−8% a year
EMBCEmbecta$1B−8% a year
VMDViemed Healthcare$301.6M+25% a year
CRMDCorMedix$462.2M+281% a year
Peer median$222.5M

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on Artiva Biotherapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.